Filing Flows › GSK (GSK) › Other Paediatric & Adult Vaccines revenue
GSK (GSK) Other Paediatric & Adult Vaccines revenue by quarter
GSK's Other Paediatric & Adult Vaccines revenue was $832M in Q3 2026 (third quarter 2026), +14% from Q2 2026. Over the last 3 quarters it ranged from $713M (Q1 2026) to $832M (Q3 2026).
| Quarter | Other Paediatric & Adult Vaccines revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $832M | +14% | — |
| Q2 2026 | $731M | +3% | — |
| Q1 2026 | $713M | — | — |
Q3 2026 at a glance
GSK, Q3 2026: revenue $8.9B (+4% year over year), operating margin 23.9%, net earnings $1.5B, operating cash flow $3.1B. The chart follows the revenue to costs, profit and cash.
Questions
What is GSK's Other Paediatric & Adult Vaccines revenue?
GSK's Other Paediatric & Adult Vaccines revenue was $832M in Q3 2026 (third quarter 2026), +14% from Q2 2026.
How has GSK's Other Paediatric & Adult Vaccines revenue changed?
Over the last 3 quarters it ranged from $713M (Q1 2026) to $832M (Q3 2026).